Clinical Trial

ASSIST-VLA: Assessment of Symptom-Specific Improvement in Diagnosed Vaginal Atrophy Following Laser Therapy

Study acronym: ASSIST-VLA
Completed Phase 4
View on ClinicalTrials.gov →
Summary
Vaginal atrophy patients receiving vaginal laser therapy will be treated with daily 7-0940® following a laser session to evaluate the safety and efficacy of the product as an adjunct treatment. Clinical outcomes will be assessed using validated investigator- and patient-reported measures, with safety and symptom progression monitored throughout the study.
Protocol Amendment History 4 changes
critical Trial completed 2026-07-21
notable Enrollment increased: 10 -> 11 participants 2026-07-21
notable Primary completion moved earlier: 2026-04 -> 2026-02-19 2026-07-21
minor Completion moved earlier: 2026-04 -> 2026-02-19 2026-07-21
Trial Details
NCT Number NCT07346287
Lead Sponsor Stratpharma AG
Conditions Vaginal Atrophy, Atrophic Vaginitis, Genitourinary Syndrome of Menopause (GSM)
Enrollment 11 participants
Start Date 2025-08-13
Primary Completion 2026-02-19 (estimated)
Study Completion 2026-02-19 (estimated)
Updated on ClinicalTrials.gov 2026-07-20